USD 3.64
(-3.96%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | -100.0% |
2021 | 210 Thousand USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - USD | -100.0% |
2024 Q2 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q4 | 372 Thousand USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 FY | - USD | -100.0% |
2022 Q4 | - USD | 0.0% |
2021 FY | 210 Thousand USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ADC Therapeutics SA | 69.55 Million USD | 100.0% |
Annovis Bio, Inc. | - USD | NaN% |
Biohaven Pharmaceutical Holding Company Ltd. | - USD | NaN% |
Ginkgo Bioworks Holdings, Inc. | 251.45 Million USD | 100.0% |
Nuvation Bio Inc. | - USD | NaN% |
Nuvation Bio Inc. | - USD | NaN% |
Arcus Biosciences, Inc. | 117 Million USD | 100.0% |
Theriva Biologics, Inc. | - USD | NaN% |
Zymeworks Inc. | 76.01 Million USD | 100.0% |